Document is current
Any future updates will be listed below
-
Authors
Siddoway, A. C.
Verhoeven, D.
Harm, T. A.
Wannemuehler, M. J.
Mallapragada, S. K.
Narasimhan, B. https://orcid.org/0000-0002-7955-5353
-
Funding
Funding for this research was provided by:
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (R01 AI141196)
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (R01 AI154458)
- License Information
-
More Information
Article History
Received: 3 February 2025
Revised: 5 July 2025
Accepted: 31 July 2025
First Online: 15 September 2025
Declarations
:
: Balaji Narasimhan and Michael Wannemuehler are co-founders of Immuno Nano Med Inc., a start-up with business interests in the development of nano-based vaccines against infectious diseases. Surya Mallapragada also has a financial interest in Immuno Nano Med Inc. David Verhoeven is chief scientific officer and founder of Syntherna, a start-up with business interests in vaccines, including equine vaccines.
